Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubenimex - Eiger Biopharmaceuticals/Nippon Kayaku

Drug Profile

Ubenimex - Eiger Biopharmaceuticals/Nippon Kayaku

Alternative Names: 1580RB; Bestatin; NK 421; Ubestatin

Latest Information Update: 23 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Microbial Chemistry
  • Developer Eiger BioPharmaceuticals, Inc.; Nippon Kayaku
  • Class Antineoplastics; Branched-chain amino acids; Dipeptides; Essential amino acids; Small molecules
  • Mechanism of Action Aminopeptidase B inhibitors; Aminopeptidase inhibitors; Immunostimulants; Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute nonlymphocytic leukaemia
  • Preclinical Inflammation
  • Discontinued HIV infections; Lymphoedema; Pulmonary arterial hypertension

Most Recent Events

  • 28 Feb 2019 Eiger BioPharmaceuticals completes the ULTRA trial for Lymphoedema in Australia and USA (NCT02700529)
  • 01 Aug 2018 Eiger BioPharmaceuticals terminates the extension phase II LIBERTY2 trial for Pulmonary arterial hypertension in USA and Canada following the failure to demonstrate efficacy in EIG-UBX-001 trial (PO) (NCT02736149)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top